A Phase 4 interventional study of Bimatoprost 0.03%, Travoprost 0.004%, Timolol 0.5% in Glaucoma, sponsored by Innovative Medical. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2007-02-09.
Sponsored by Innovative Medical · Phase 4 and Interventional
Evaluate the IOP-lowering efficacy and quality of life in patients using bimatoprost 0.03% monotherapy versus dual therapy with travoprost 0.004% and timolol 0.5% for the treatment of glaucoma or ocular hypertension.
1,818 studies on the registry are indexed under Glaucoma; 231 are open to participants now.
Browse Glaucoma studies →Innovative Medical is the lead sponsor of 50 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Male or female > 18 years of age
Exclusion Criteria:
Known contraindication to bimatoprost, travoprost, timolol, or any component of any study medication
This study is completed, as verified in Feb 2007. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Innovative Medical